Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Swedish Orphan Biovitrum AB (publ)
Sobi is a biopharma company that develops and sells medicines for rare diseases, mainly in haematology and immunology.
Sobi is a Swedish drugmaker that focuses on rare diseases — the kind of conditions that are too uncommon for most big pharmaceutical companies to build a business around. It sells medicines in two main areas: haematology (blood disorders) and immunology (immune system problems), plus a smaller specialty care business. Its customers are hospitals, doctors and healthcare systems that need treatments for patients with few other options.
The money comes from selling these medicines, often at high prices because the patient groups are small and the development is hard. Sobi's best-known products treat bleeding disorders like haemophilia and inflammatory conditions. It doesn't just invent everything itself — a lot of its growth has come from licensing drugs from other companies, buying them, and then marketing them across Europe and beyond. That model works because Sobi has built sales teams and regulatory know-how in markets where small biotechs can't easily reach patients on their own. The company is headquartered in Stockholm and listed on Nasdaq Stockholm. It has grown steadily through deals, including a big one that brought in a promising treatment for a rare blood disease, and it invests heavily in late-stage trials to widen the labels of drugs it already owns. The appeal to investors is that rare-disease medicines face less competition and enjoy strong pricing power, though they also carry risk: a single failed trial or a patent expiring can hurt a lot when your portfolio is concentrated.
Sobi's main challenge is that it competes with much larger players in haematology and immunology, and it depends on a handful of key products for a big share of its revenue. It spends its cash on research, on buying or licensing new drugs, and on expanding into new markets rather than paying big dividends. The bet is that niche medicine, done well, is a durable business — small patient pools, but loyal ones.
Saved answer · last researched 12 Nov 2026